AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16613261 — intervention group
Group type: EXPERIMENTAL
Intervention: LGT + PRO
Number of subjects: 36
Study 16613261 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 36
Study 12745849 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcitriol 3 microg/g ointment
Number of subjects: 258
Study 12745849 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone dipropionate 0.05% ointment
Number of subjects: 258
Study 10960927 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly emotional standardized role-playing sessions (HE-SRPS)
Number of subjects: 25
Study 10960927 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderately emotional standardized role-playing sessions (ME-SRPS)
Number of subjects: 25
Study 10960927 — intervention group
Group type: EXPERIMENTAL
Intervention: Weakly emotional standardized role-playing sessions (WE-SRPS)
Number of subjects: 25
Study 8953103 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin, clinafloxacin, sparfloxacin, trovafloxacin, grepafloxacin, DU-6859a
Number of subjects: 0
Study 8953103 — intervention group
Group type: EXPERIMENTAL
Intervention: New fluoroquinolones
Number of subjects: 0
Study 8953103 — intervention group
Group type: EXPERIMENTAL
Intervention: Other fluoroquinolones
Number of subjects: 0
Study 1444880 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl levocarnitine hydrochloride (2.5 g/d for 3 months followed by 3 g/d for 3 months)
Number of subjects: 30
Study 1444880 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 1444880 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl levocarnitine hydrochloride
Number of subjects: 30
Study 3969859 — intervention group
Group type: EXPERIMENTAL
Intervention: Medically directed at-home rehabilitation
Number of subjects: 127
Study 3969859 — intervention group
Group type: COMPARATOR
Intervention: Group rehabilitation
Number of subjects: 127
Study 3969859 — intervention group
Group type: COMPARATOR
Intervention: Overall study population (including control patients)
Number of subjects: 127
Study 29800180 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained supplementation with 400 IU/d of cholecalciferol until 6 months of age adjusted for prematurity
Number of subjects: 300
Study 29800180 — intervention group
Group type: COMPARATOR
Intervention: Diet-limited supplementation (placebo)
Number of subjects: 300
Study 27150293 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal ablation with irreversible electroporation (IRE)
Number of subjects: 200
Study 27150293 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended ablation with irreversible electroporation (IRE)
Number of subjects: 200
Study 25107877 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirror therapy (MT)
Number of subjects: 48
Study 22151608 — intervention group
Group type: EXPERIMENTAL
Intervention: tenofovir/emtricitabine with efavirenz (arm 1)
Number of subjects: 28
Study 22151608 — intervention group
Group type: EXPERIMENTAL
Intervention: atazanavir/ritonavir (arm 2)
Number of subjects: 28
Study 22151608 — intervention group
Group type: EXPERIMENTAL
Intervention: zidovudine/abacavir (arm 3)
Number of subjects: 28
Study 20012550 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-TNF treatment (group 1, n=23)
Number of subjects: 47
Study 20012550 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAIDs treatment (group 2, n=24)
Number of subjects: 47
Study 20012550 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy controls, n=27)
Number of subjects: 47
Study 20012550 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison between group 1 and group 2
Number of subjects: 47
Study 17071040 — intervention group
Group type: EXPERIMENTAL
Intervention: Angioseal device
Number of subjects: 100
Study 17071040 — intervention group
Group type: COMPARATOR
Intervention: Manual compression
Number of subjects: 100
Study 17071040 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 16287668 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear-avoidance beliefs for work
Number of subjects: 93
Study 16287668 — intervention group
Group type: EXPERIMENTAL
Intervention: Disability
Number of subjects: 93
Study 16287668 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular fitness
Number of subjects: 93
Study 16287668 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall return to work
Number of subjects: 93
Study 16287668 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct predictions
Number of subjects: 93
Study 11887533 — intervention group
Group type: EXPERIMENTAL
Intervention: Mineral trioxide aggregate
Number of subjects: 33
Study 11887533 — intervention group
Group type: EXPERIMENTAL
Intervention: Super EBA
Number of subjects: 33
Study 11887533 — intervention group
Group type: EXPERIMENTAL
Intervention: IRM
Number of subjects: 33
Study 11887533 — intervention group
Group type: COMPARATOR
Intervention: Varnished negative control
Number of subjects: 33
Study 9748085 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise
Number of subjects: 8
Study 9748085 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity exercise
Number of subjects: 8
Study 9748085 — intervention group
Group type: COMPARATOR
Intervention: Seated rest
Number of subjects: 8
Study 7661729 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive subjects
Number of subjects: 178
Study 7661729 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain-damaged hypertensive subjects
Number of subjects: 178
Study 7661729 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 178
Study 2752716 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg lomefloxacin, given orally twice daily for 2 weeks
Number of subjects: 12
Study 2752716 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered to four subjects
Number of subjects: 12
Study 793549 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (aortocoronary bypass)
Number of subjects: 116
Study 793549 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 116
Study 30928969 — intervention group
Group type: COMPARATOR
Intervention: web‐based lifestyle advice only (lifestyle group)
Number of subjects: 956
Study 30928969 — intervention group
Group type: COMPARATOR
Intervention: lifestyle advice plus information on estimated 10‐year coronary heart disease risk based on phenotypic characteristics (phenotypic group)
Number of subjects: 956
Study 30928969 — intervention group
Group type: COMPARATOR
Intervention: lifestyle advice plus information on estimated 10‐year coronary heart disease risk based on phenotypic (phenotypic risk estimate) and genetic characteristics (genetic group)
Number of subjects: 956
Study 30928969 — intervention group
Group type: COMPARATOR
Intervention: phenotypic group and genetic group
Number of subjects: 956
Study 28183314 — intervention group
Group type: EXPERIMENTAL
Intervention: Linagliptin
Number of subjects: 46
Study 28183314 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 25982678 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiamine supplementation (3 × 100 mg/day for six weeks)
Number of subjects: 12
Study 25982678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 22562227 — intervention group
Group type: EXPERIMENTAL
Intervention: Webinars (WL)
Number of subjects: 58
Study 22562227 — intervention group
Group type: COMPARATOR
Intervention: Participatory learning (PL)
Number of subjects: 58
Study 21788954 — intervention group
Group type: EXPERIMENTAL
Intervention: WISCI II level with no devices or braces and 1 person assistance
Number of subjects: 42
Study 21788954 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking with assistance
Number of subjects: 42
Study 21788954 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking without assistance and more devices
Number of subjects: 42
Study 19657891 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based asthma monitoring and data collection system
Number of subjects: 323
Study 17034435 — intervention group
Group type: EXPERIMENTAL
Intervention: Topiramate
Number of subjects: 150
Study 17034435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 15624735 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) and blue light (405-420 nm) for 15 minutes
Number of subjects: 12
Study 15624735 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) and intense pulsed light (IPL, 500-1,200 nm)
Number of subjects: 12
Study 10843478 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy and cytology
Number of subjects: 322
Study 10843478 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy
Number of subjects: 322
Study 10843478 — intervention group
Group type: EXPERIMENTAL
Intervention: Colposcopy after therapy
Number of subjects: 322
Study 10843478 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-DNA testing by PCR
Number of subjects: 322
Study 10843478 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV-DNA testing
Number of subjects: 322
Study 10843478 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4+ T-lymphocytes
Number of subjects: 322
Study 9171795 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaxial catheter method for sequential spiral CT during arterial portography (CTAP) and hepatic arteriography (CTA)
Number of subjects: 16
Study 9171795 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of CTAP and CTA
Number of subjects: 16
Study 9171795 — intervention group
Group type: EXPERIMENTAL
Intervention: Coaxial catheter method
Number of subjects: 16
Study 8266220 — intervention group
Group type: EXPERIMENTAL
Intervention: Permethrin-treated nets
Number of subjects: 399
Study 8266220 — intervention group
Group type: COMPARATOR
Intervention: Untreated nets
Number of subjects: 399
Study 3519348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 62
Study 3519348 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 62
Study 3519348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 3281786 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral verapamil alone at a dose of 80 mg three times daily
Number of subjects: 8
Study 3281786 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 40 mg of verapamil three times daily with 0.25 mg of digoxin daily
Number of subjects: 8
Study 3281786 — intervention group
Group type: COMPARATOR
Intervention: Digoxin alone
Number of subjects: 8
Study 31590637 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) score 3-4
Number of subjects: 124721
Study 31590637 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) score 5-6
Number of subjects: 124721
Study 31590637 — intervention group
Group type: EXPERIMENTAL
Intervention: Charlson Comorbidity Index (CCI) score > 6
Number of subjects: 124721
Study 31590637 — intervention group
Group type: COMPARATOR
Intervention: No comorbidity (CCI = 2)
Number of subjects: 124721
Study 28555092 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrodotoxin (TTX) 30 μg subcutaneously twice daily for four consecutive days
Number of subjects: 165
Study 28555092 — intervention group
Group type: COMPARATOR
Intervention: Placebo subcutaneously twice daily for four consecutive days
Number of subjects: 165
Study 25296741 — intervention group
Group type: EXPERIMENTAL
Intervention: High Velocity Low Amplitude (HVLA) manipulation
Number of subjects: 48
Study 25296741 — intervention group
Group type: EXPERIMENTAL
Intervention: Posteroanterior mobilization (PA mob)
Number of subjects: 48
Study 25296741 — intervention group
Group type: COMPARATOR
Intervention: Sustain Apophyseal Natural Glide (SNAG)
Number of subjects: 48
Study 25296741 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical Range of Motion (CROM)
Number of subjects: 48
Study 25296741 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS in Flexion/Extension
Number of subjects: 48
Study 25296741 — intervention group
Group type: EXPERIMENTAL
Intervention: CROM in Lateral-Flexion movement
Number of subjects: 48
Study 23118007 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with depressed heart rate variability (HRV) (≤6.5%)
Number of subjects: 108
Study 23118007 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with bundle branch block (BBB) and large QRS dispersion (>39 ms)
Number of subjects: 108
Study 23118007 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without BBB with reduced maximum T-wave amplitude (<0.4 mV)
Number of subjects: 108
Study 23118007 — intervention group
Group type: EXPERIMENTAL
Intervention: History of atrial arrhythmia
Number of subjects: 108
Study 23118007 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary prevention
Number of subjects: 108
Study 21646935 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestipitant
Number of subjects: 24
Study 21646935 — intervention group
Group type: EXPERIMENTAL
Intervention: Vestipitant and Paroxetine combination
Number of subjects: 24
Study 21646935 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 17614015 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (walking and light weight lifting for one hour, 3 times/week)
Number of subjects: 213
Study 17070157 — intervention group
Group type: EXPERIMENTAL
Intervention: Probucol (1 g/d)
Number of subjects: 59
Study 17070157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 14628586 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (AC) combined with drug therapy
Number of subjects: 90
Study 14628586 — intervention group
Group type: COMPARATOR
Intervention: Combined drug therapy
Number of subjects: 90
Study 10902986 — intervention group
Group type: EXPERIMENTAL
Intervention: E = 1171 kJ + 12 mg iron
Number of subjects: 136
Study 10902986 — intervention group
Group type: EXPERIMENTAL
Intervention: M = 209 kJ + 12 mg iron
Number of subjects: 136
Study 10902986 — intervention group
Group type: EXPERIMENTAL
Intervention: S = 104 kJ
Number of subjects: 136
Study 9552817 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole lacquer applied on upper denture base on days 0, 7, and 14
Number of subjects: 21
Study 9552817 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole lacquer
Number of subjects: 21
Study 9552817 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 denture wearers)
Number of subjects: 21
Study 1304210 — intervention group
Group type: EXPERIMENTAL
Intervention: HEMA posterior chamber lens implanted through a 3.5 mm scleral tunnel incision
Number of subjects: 70
Study 1304210 — intervention group
Group type: COMPARATOR
Intervention: PMMA posterior chamber lens implanted through a 7 mm scleral step incision
Number of subjects: 70
Study 3885982 — intervention group
Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 0
Study 3885982 — intervention group
Group type: COMPARATOR
Intervention: Althesin
Number of subjects: 0
Study 31313093 — intervention group
Group type: EXPERIMENTAL
Intervention: HITSystem (eHealth intervention)
Number of subjects: 137
Study 31313093 — intervention group
Group type: COMPARATOR
Intervention: Control (standard EID services)
Number of subjects: 137
Study 30057233 — intervention group
Group type: EXPERIMENTAL
Intervention: MAVIG lead shield
Number of subjects: 125
Study 30057233 — intervention group
Group type: EXPERIMENTAL
Intervention: RADPAD shield
Number of subjects: 125
Study 30057233 — intervention group
Group type: COMPARATOR
Intervention: Control group (no shield)
Number of subjects: 125
Study 26809601 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 99
Study 26809601 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Number of subjects: 99
Study 26809601 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Usual Care
Number of subjects: 99
Study 24028708 — intervention group
Group type: EXPERIMENTAL
Intervention: Low calcium dialysate (1.25 mmol/L)
Number of subjects: 40
Study 24028708 — intervention group
Group type: COMPARATOR
Intervention: Standard calcium dialysate (1.75 mmol/L)
Number of subjects: 40
Study 22376791 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest therapy for 10 weeks with a recommendation to rest for two hours daily and the option of using a flexible lumbar belt
Number of subjects: 100
Study 22376791 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy once a week for 10 weeks
Number of subjects: 100
Study 20888994 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (fludarabine, cyclophosphamide, and rituximab)
Number of subjects: 817
Study 20888994 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (fludarabine and cyclophosphamide)
Number of subjects: 817
Study 18391846 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin treatment for 3 months
Number of subjects: 16
Study 18391846 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 18391846 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 16
Study 18391846 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy children)
Number of subjects: 16
Study 15920216 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 0
Study 15920216 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane
Number of subjects: 0
Study 15920216 — intervention group
Group type: EXPERIMENTAL
Intervention: Crossover design (substituting anesthetics)
Number of subjects: 0
Study 11964956 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 g/dL oligosaccharides
Number of subjects: 90
Study 11964956 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/dL oligosaccharides
Number of subjects: 90
Study 11964956 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 90
Study 10214007 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural block only during operations (group M)
Number of subjects: 0
Study 10214007 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion for 2 postoperative days (group B 2)
Number of subjects: 0
Study 10214007 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous epidural infusion for 4 postoperative days (group B 4)
Number of subjects: 0
Study 10214007 — intervention group
Group type: COMPARATOR
Intervention: Control group (group M)
Number of subjects: 0
Study 10214007 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of verbal descriptor pain score
Number of subjects: 0
Study 10214007 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal pain after catheter removal
Number of subjects: 0
Study 7888887 — intervention group
Group type: EXPERIMENTAL
Intervention: Algorithm and instant developing camera
Number of subjects: 50
Study 7888887 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 50
Study 7888887 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention city
Number of subjects: 50
Study 7888887 — intervention group
Group type: COMPARATOR
Intervention: Control city
Number of subjects: 50
Study 2211560 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 6
Study 2211560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2211560 — intervention group
Group type: COMPARATOR
Intervention: Trimipramine
Number of subjects: 6
Study 45210 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 micrograms oxitropium bromide
Number of subjects: 19
Study 45210 — intervention group
Group type: COMPARATOR
Intervention: 40 micrograms ipratropium bromide
Number of subjects: 19
Study 45210 — intervention group
Group type: COMPARATOR
Intervention: 400 micrograms fenoterol
Number of subjects: 19
Study 45210 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 29510745 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous dendritic cell vaccines (DCV) with 500 micrograms of GM-CSF, injected weekly for 3 weeks, then at weeks 8, 12, 16, 20, and 24.
Number of subjects: 42
Study 29510745 — intervention group
Group type: COMPARATOR
Intervention: Autologous tumor cell vaccines (TCV) with 500 micrograms of GM-CSF, injected weekly for 3 weeks, then at weeks 8, 12, 16, 20, and 24.
Number of subjects: 42
Study 26828571 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training plus work therapy (n = 15)
Number of subjects: 31
Study 26828571 — intervention group
Group type: COMPARATOR
Intervention: Work therapy alone (n = 16)
Number of subjects: 31
Study 24649895 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional telephone counseling session performed by psychosocial workers
Number of subjects: 264
Study 24649895 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 264
Study 22734829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (vaporiser-dial setting, 1.5%) during one-lung ventilation
Number of subjects: 8
Study 22734829 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (vaporiser-dial setting, 1.5%) during two-lung ventilation
Number of subjects: 8
Study 21246573 — intervention group
Group type: EXPERIMENTAL
Intervention: 607-nm pulsed dye laser
Number of subjects: 10
Study 21246573 — intervention group
Group type: COMPARATOR
Intervention: 595-nm pulsed dye laser
Number of subjects: 10
Study 17080447 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week internet-based prevention program
Number of subjects: 100
Study 17080447 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control condition
Number of subjects: 100
Study 16307621 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational multimedia computer program
Number of subjects: 194
Study 16307621 — intervention group
Group type: COMPARATOR
Intervention: Usual nurse counseling
Number of subjects: 194
Study 11896508 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (A)
Number of subjects: 27
Study 11896508 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (B)
Number of subjects: 27
Study 11896508 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine + Benazepril (A+B)
Number of subjects: 27
Study 11896508 — intervention group
Group type: COMPARATOR
Intervention: Control (A alone)
Number of subjects: 27
Study 9670386 — intervention group
Group type: EXPERIMENTAL
Intervention: Zancolli classification
Number of subjects: 0
Study 9670386 — intervention group
Group type: EXPERIMENTAL
Intervention: ASIA motor score
Number of subjects: 0
Study 7851108 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental treatment E
Number of subjects: 0